[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,029,844
  • Shares Outstanding, K 133,513
  • Annual Sales, $ 3,714 M
  • Annual Income, $ 313,750 K
  • EBIT $ 752 M
  • EBITDA $ 808 M
  • 60-Month Beta 0.31
  • Price/Sales 10.61
  • Price/Cash Flow 105.52
  • Price/Book 36.63

Options Overview Details

View History
  • Implied Volatility 39.98% (-0.49%)
  • Historical Volatility 38.30%
  • IV Percentile 32%
  • IV Rank 41.26%
  • IV High 54.81% on 01/09/26
  • IV Low 29.56% on 08/13/25
  • Expected Move (DTE 2) 6.65 (2.28%)
  • Put/Call Vol Ratio 1.35
  • Today's Volume 802
  • Volume Avg (30-Day) 627
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 24,931
  • Open Int (30-Day) 22,550
  • Expected Range 285.38 to 298.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.54
  • Number of Estimates 9
  • High Estimate $1.91
  • Low Estimate $1.00
  • Prior Year $-0.52
  • Growth Rate Est. (year over year) +396.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
284.28 +2.73%
on 05/11/26
343.36 -14.95%
on 04/14/26
-30.08 (-9.34%)
since 04/10/26
3-Month
284.28 +2.73%
on 05/11/26
345.89 -15.57%
on 02/20/26
-16.45 (-5.33%)
since 02/12/26
52-Week
261.45 +11.70%
on 05/13/25
495.55 -41.07%
on 10/20/25
+21.84 (+8.08%)
since 05/12/25

Most Recent Stories

More News
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies – ...

ALNY : 292.03 (+2.52%)
Alnylam to Webcast Presentations at Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:...

ALNY : 292.03 (+2.52%)
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Alnylam Pharmaceuticals, Inc . (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type...

ALNY : 292.03 (+2.52%)
Alnylam: Q1 Earnings Snapshot

Alnylam: Q1 Earnings Snapshot

ALNY : 292.03 (+2.52%)
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress

− Achieved First Quarter 2026 Global Net Product Revenues of $1,036 Million (121% Growth Compared with Q1 2025), Driven Primarily by Total TTR Revenues of $910 Million (153% Growth Compared with Q1 2025)...

ALNY : 292.03 (+2.52%)
Alnylam's Earnings Tomorrow Could Validate the Case That RNAi Has Finally Arrived

Barchart Research What to Expect from ALNY Earnings ALNY Generated April 29, 2026 Current Price $301.19 EPS Estimate $$0.91 Consensus Rating Moderate Buy Average Move 6.06% Alnylam's Earnings Tomorrow...

ALNY : 292.03 (+2.52%)
Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2026 on Thursday,...

ALNY : 292.03 (+2.52%)
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

− Vutrisiran, which Silences Transthyretin at the Source, Shown to Improve Health-Related Quality-of-Life in Those with ATTR-CM, with Treatment Effects Comparable to Patients More than Ten Years Younger...

ALNY : 292.03 (+2.52%)
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

− Efforts Aimed at Facilitating Earlier Diagnosis, Coordinated Care, and Long-Term Patient Impact in ATTR-CM – − Alnylam to Host TTR Investor Webinar Today at 9:30...

ALNY : 292.03 (+2.52%)
Is Incyte Stock Outperforming the Dow?

Incyte has outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.

ALNY : 292.03 (+2.52%)
INCY : 99.13 (-1.19%)
$DOWI : 49,760.56 (+0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 305.49
2nd Resistance Point 300.67
1st Resistance Point 296.35
Last Price 292.03
1st Support Level 287.22
2nd Support Level 282.40
3rd Support Level 278.08

See More

52-Week High 495.55
Fibonacci 61.8% 406.12
Fibonacci 50% 378.50
Fibonacci 38.2% 350.88
Last Price 292.03
52-Week Low 261.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.